Ambu A/ S stock (DK0060946788): investors eye single-use endoscopy momentum after latest quarterly update

Ambu A/S has updated investors on its fiscal 2024/25 performance, highlighting trends in single?use endoscopy and hospital spending while the stock remains in focus for medtech exposure.

Ambu A/S, the Danish medtech group known for single?use endoscopes and anesthesia equipment, recently released results for the second quarter of its fiscal year 2024/25, giving fresh insight into growth, profitability and demand trends across key product lines, according to a company update published on 05/07/2025 on its investor website and follow-up coverage the same day by international financial media (Ambu investor update as of 05/07/2025; Reuters as of 05/07/2025).

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Ambu A/S
• Sector/industry: Medical technology, single?use endoscopy and patient monitoring
• Headquarters/country: Ballerup, Denmark
• Core markets: Hospitals and clinics in Europe, North America and selected Asia?Pacific countries
• Key revenue drivers: Single?use endoscopy systems, anesthesia consumables, patient monitoring and diagnostics
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: AMBU-B)
• Trading currency: Danish krone (DKK)

Ambu A/S: core business model

Ambu A/S operates as a specialized medical technology company focused on single?use devices for hospitals and clinics. The group has built a strong position in single?use endoscopy, where it supplies disposable bronchoscopes, ENT and other scopes, typically used together with Ambu visualization platforms in operating rooms and intensive care units, according to its corporate profile and product documentation on its website (Ambu company information as of 04/2025).

Alongside endoscopy, Ambu generates revenue from anesthesia consumables, including airway management products and resuscitation devices, as well as patient monitoring and diagnostic electrodes. These segments provide recurring demand linked to procedure volumes rather than large capital purchases, which can help smooth revenue compared with capital?intensive equipment makers, according to product descriptions and historical commentary in past investor materials (Ambu product overview as of 03/2025).

The company’s strategy emphasizes infection control and workflow efficiency in hospitals by replacing reusable endoscopes with single?use alternatives. This approach seeks to remove complex reprocessing steps, reduce cross?contamination risk and support hospitals that struggle with staffing and sterilization capacity. Management has repeatedly highlighted these structural trends as drivers behind the expansion of single?use endoscopy adoption, according to recent presentations and earnings commentary (Ambu presentations as of 2025).

Main revenue and product drivers for Ambu A/S

Ambu’s main growth engine is its single?use endoscopy segment, which includes bronchoscopes for pulmonary procedures, ENT scopes and solutions for gastroenterology and urology. Management reported that single?use endoscopy delivered organic revenue growth in the mid? to high?single?digit range in the second quarter of fiscal 2024/25, supported by higher procedure volumes and new account wins, according to the company’s Q2 2024/25 announcement published on 05/07/2025 (Ambu Q2 2024/25 report as of 05/07/2025).

In addition to endoscopy, Ambu’s anesthesia business continues to represent a sizable part of group revenue through single?use airways, resuscitators and related products used in emergency medicine and operating rooms. These items are typically purchased as consumables and linked closely to hospital patient volumes. The patient monitoring and diagnostics segment, including BlueSensor ECG electrodes and similar products, adds another recurring revenue stream tied to routine monitoring and diagnostic activities in hospitals and outpatient settings (Ambu patient monitoring overview as of 02/2025).

Management comments around the Q2 2024/25 release emphasized continued focus on profitability improvements, including cost discipline and product mix optimization toward higher?margin devices. The report indicated that operational initiatives and scale effects in single?use endoscopy were contributing to margin development, while the company also monitored hospital capital spending patterns, particularly for visualization systems that complement its disposable scopes (Ambu Q2 2024/25 report as of 05/07/2025).

Industry trends and competitive position

The broader medtech sector has seen growing interest in single?use instruments as hospitals aim to reduce infection risks and simplify workflows. This has been particularly visible in endoscopy, where reprocessing reusable scopes can be labor?intensive and subject to regulatory scrutiny. Ambu positions itself as a pioneer in single?use endoscopes, competing against both traditional reusable device makers and other single?use entrants, according to its strategic presentations and market descriptions (Ambu presentations as of 2025).

In North America, where Ambu has been expanding its presence, hospital systems represent an important growth opportunity. The company has indicated that adoption of single?use devices is influenced by infection?prevention policies, staff availability and cost?benefit analyses that include reprocessing costs for reusable equipment. This backdrop, together with health?system consolidation in the United States, makes the region a strategically significant market for Ambu’s endoscopy and anesthesia offerings (Ambu global presence overview as of 2025).

At the same time, competition remains intense, and hospitals may review total cost of ownership when comparing single?use and reusable solutions. This can lead to differentiated adoption rates across regions and specialties. Ambu’s ability to innovate, gain procedure approvals and secure long?term contracts with hospitals and group purchasing organizations is therefore a key factor shaping its competitive position in the single?use medtech niche, according to sector commentary in financial media and industry publications (Reuters company profile as of 04/2025).

Why Ambu A/S matters for US investors

For US investors, Ambu offers exposure to structural themes in global healthcare, including infection prevention, the shift to outpatient and minimally invasive procedures, and a broader move toward disposable medical devices. Although the stock is listed on Nasdaq Copenhagen in Danish krone, a substantial share of its growth potential is linked to North American hospitals and procedure volumes, which connect directly to the US healthcare economy (Ambu global presence overview as of 2025).

Investors in the United States following international medtech names often focus on how companies balance innovation with regulatory requirements and reimbursement dynamics. Ambu’s efforts to expand its portfolio of single?use endoscopes and related visualization systems, while pursuing profitability improvements, align with themes monitored closely in the US medical device sector. Access for US investors typically occurs via international brokerage platforms that provide trading on European exchanges, and currency movements between the US dollar and Danish krone can influence returns when translated into dollars (Ambu investor information as of 05/2025).

Conclusion

Ambu A/S offers investors exposure to hospital procedure trends and the growing adoption of single?use endoscopy, with its latest Q2 2024/25 results underlining steady organic growth and ongoing work on profitability, according to the company’s 05/07/2025 update. The business remains tied to hospital capital spending and regulatory dynamics in key markets, but its focus on infection control and consumable?driven revenue gives it a distinct profile within global medtech. For US investors following international healthcare names, Ambu’s combination of single?use innovation, European listing and North American growth ambitions may warrant continued monitoring as hospitals refine their approach to endoscopy and patient monitoring technologies.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.